Advertisement
UK markets closed

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • FTSE 250

    20,164.54
    +112.21 (+0.56%)
     

  • AIM

    771.53
    +3.42 (+0.45%)
     

  • GBP/EUR

    1.1652
    -0.0031 (-0.26%)
     

  • GBP/USD

    1.2546
    +0.0013 (+0.11%)
     

  • Bitcoin GBP

    50,248.81
    +212.96 (+0.43%)
     

  • CMC Crypto 200

    1,313.86
    +36.88 (+2.89%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • HANG SENG

    18,475.92
    +268.79 (+1.48%)
     

  • DAX

    18,001.60
    +105.10 (+0.59%)
     

  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     
MONEY:

Best savings accounts that offer above inflation rates

Where to find a top-rated deal that works for you

BUZZ-AstraZeneca: investor survey sees 50:50 chance for cancer combo

Reuters - UK Focus

** AstraZeneca (NYSE: AZN - news) clinical trial combining durvalumab and tremelimumab in first-line lung cancer has 50% chance of success, according to median prediction from 255 investors polled by Evercore ISI

** Bristol-Myers Squibb's similar Opdivo/Yervoy combo given 60% chance

** Combination treatment for first-line lung cancer key focus after weekend ESMO meeting, where Merck (LSE: 0O14.L - news) 's Keytruda stole show for selected patients with high PD-L1 levels

** AstraZeneca's MYSTIC combo trial expected to report results first half next year, with Bristol's CM-227 seen in 2018